SEPREHVIR® is an oncolytic immunotherapy derived from a modified version of the common human herpes simplex virus (HSV-1).
SEPREHVIR has been designed with the ability to target and destroy tumour cells and leave normal healthy cells unharmed. In addition, death of the targeted cancer cell can stimulate an anti-tumour T-cell mediated immune response not only in injected but also non-injected tumours.
Stimulating a patient's own immune system to develop effective anti-tumour immune responses that eradicate cancers, known as “immunotherapy”, has been an important breakthrough in cancer therapy.
The data being generated from Virttu’s pre-clinical and clinical studies suggests SEPREHVIR has significant potential as an oncolytic immunotherapy.
We are conducting clinical studies in a wide range of cancer types in leading medical centres in the USA and Europe.